• HealthEquity, Inc. has already reported its first-quarter fiscal 2027 results for the period ended April 30, 2026, with revenue of US$354.64 million and net income of US$69.42 million, alongside higher basic and diluted earnings per share than a year earlier.
• Management also raised full-year fiscal 2027 guidance and expanded the share repurchase authorization after completing buybacks of 2,842,781 shares, pointing to confidence in earnings power and capital return capacity.
• We’ll now examine how HealthEquity’s upgraded fiscal 2027 outlook and AI-driven efficiency gains influence the company’s existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

HealthEquity Investment Narrative Recap

To own HealthEquity, you need to believe in long term growth in HSA adoption and the company’s ability to convert that into resilient, diversified earnings. The latest results and upgraded fiscal 2027 outlook reinforce the near term catalyst around AI enabled efficiency and margin gains, while the key risk remains sensitivity to interest income and broader employment trends. This quarter’s news does not remove that risk, but it does suggest it is not currently the dominant driver of results.

The most relevant update here is management’s raised fiscal 2027 guidance to US$1.410 billion to US$1.420 billion in revenue and US$2.88 to US$2.95 in diluted EPS. That outlook sits alongside higher Q1 profitability and an expanded US$1.0 billion repurchase authorization, which together support the idea that technology investment and AI driven efficiencies are already contributing meaningfully to margins and could remain an important short term catalyst if execution holds.

Yet investors should also be aware of how exposed HealthEquity remains if interest income on custodial cash were to...

HealthEquity’s narrative projects $1.6 billion revenue and $339.8 million earnings by 2029.

Uncover how HealthEquity's forecasts yield a $112.88 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community value HealthEquity between US$97.01 and US$167.18 per share, showing a wide spread of opinions. When you set those views against the raised fiscal 2027 guidance and AI efficiency gains, it underlines how differently people can weigh growth catalysts, so it is worth examining several of these perspectives side by side.

Explore 3 other fair value estimates on HealthEquity - why the stock might be worth just $97.01!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your HealthEquity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free HealthEquity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate HealthEquity's overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 46 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.